Pegylated alpha interferon is an effective treatment for virulent venezuelan equine encephalitis virus and has profound effects on the host immune response to infection

Journal of Virology

Volumn 74, Issue 11, 2000, Pages 5006-5015

  Lukaszewski, Roman A ^a   Brooks, Timothy J G ^a  

^a DEFENCE SCIENCE AND TECHNOLOGY LABORATORY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; MACROGOL; RECOMBINANT ALPHA INTERFERON AD; RECOMBINANT INTERLEUKIN 12; TUMOR NECROSIS FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE ACTIVATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; FEMALE; IMMUNE RESPONSE; IMMUNOMODULATION; MACROPHAGE ACTIVATION; MOSQUITO; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; VENEZUELAN EQUINE ENCEPHALOMYELITIS ALPHAVIRUS; VIRUS IMMUNITY; VIRUS TRANSMISSION; VIRUS VIRULENCE;

ANIMALS; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; ANTIVIRAL AGENTS; B-LYMPHOCYTES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE; CRICETINAE; ENCEPHALITIS VIRUS, VENEZUELAN EQUINE; ENCEPHALOMYELITIS, VENEZUELAN EQUINE; FEMALE; INHALATION EXPOSURE; INJECTIONS, SUBCUTANEOUS; INTERFERON ALFA-2A; INTERLEUKIN-12; INTERLEUKIN-4; MICE; MICE, INBRED BALB C; POLYETHYLENE GLYCOLS; VIRULENCE;

EID: 0034023856     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.74.11.5006-5015.2000     Document Type: Article

References (42)

1. Alzona. M., H. M. Jack, R. I. Fisher, and T. M. Ellis. 1995. IL-12 activates IFN-g production through the preferential activation of CD30+ T cells. J. Immunol. 154:9-16.
2. Biron, C. A. 1994. Cytokines in the generation of immune responses to, and resolution of, virus infection. Curr. Opin. Immunol. 6:530-538.
3. Brooks. T. J. G., and R. J. Phillpotts. 1999. Interferon-alpha protects mice against lethal infection with St. Louis encephalitis virus delivered by the aerosol and subcutaneous routes. Antiviral Res. 41:57-64.
4. Carr, J. A., J. Rogerson, M. J. Mulqueen. N. A. Roberts, and R. F. Booth. 1997. Interleukin-12 exhibits potent antiviral activity in experimental herpesvirus infections. J. Virol. 71:7799-7803.
5. Charles, P. C., K. W. Brown, N. L. Davis, M. K. Hart, and R. E. Johnston. 1997. Mucosal immunity induced by parenteral immunisation with a live attenuated Venezuelan equine encephalitis virus vaccine candidate. Virology 228:153-160.
6. Coussens, L. P., R. Peterson, S. Hsu, A. Dorner, J. D. Altman, and C. A. Biron. 1999. Two roads diverged: interferon alpha/beta- and interleukin 12-mediated pathways in promoting T cell interferon gamma responses during viral infection. J. Exp. Med. 189:1315-1328.
7. Davis, N. L., F. B. Grieder, J. F. Smith, G. F. Greenwald, M. L. Valenski, D. C. Sellon, P. C. Charles, and R. E. Johnston. 1994. A molecular genetic approach to the study of Venezuelan equine encephalitis virus pathogenesis. Arch. Virol. Suppl. 9:99-109.
8. Gern, J. E., R. Vritis, E. A. B. Kelly, E. C. Dick, and W. W. Busse. 1996. Rhinovirus produces non-specific activation of lymphocytes through a monocyte-dependent mechanism. J. Immunol. 157:1605-1612.
9. Gerosa, F., M. Tomassi, G. Garra, G. Gandini, G. Tridente, and C. Benati. 1992. Different sensitivity to interleukin 4 of interleukin 2 and interferon alpha-induced CD69 expression in human resting NK cells and CD3+, CD4-, CD8-lymphocytes. Cell. Immunol. 141:342-351.
10. Greenway, T. E., J. H. Eldridge, G. Ludwig, J. K. Staas, J. F. Smith, R. M. Gilley, and S. M. Michalek. 1998. Induction of protective immune responses against Venezuelan equine encephalitis (VEE) virus aerosol challenge with microencapsulated VEE virus vaccine. Vaccine 16:1314-1323.
11. Grieder, F. B., B. K. Davis, X. D. Zhou, S. J. Chen, F. D. Finkelman, and W. C. Gause. 1997. Kinetics of cytokine expression and regulation of host protection following infection with molecularly cloned Venezuelan equine encephalitis virus. Virology 233:302-312.
12. Grieder, F. B., N. L. Davis, J. F. Aronson, P. C. Charles, D. C. Sellon, K. Suzuki, and R. E. Johnston. 1995. Specific restrictions in the progression of Venezuelan equine encephalitis virus-induced disease resulting from single amino acid changes in the glycoproteins. Virology 206:994-1006.
13. Grieder, F. B., and H. T. Nguyen. 1996. Virulent and attenuated mutant Venezuelan equine encephalitis virus show marked differences in replication in infection in murine macrophages. Microb. Pathog. 21:85-95.
14. Grieder, F. B., and S. N. Vogel. 1999. Role of interferon and interferon regulatory factors in early protection against Venezuelan equine encephalitis virus infection. Virology 257:106-118.
15. Huprikar, J., M. C. Dal Canto, and S. G. Rabinowitz. 1990. Protection against lethal Venezuelan equine encephalitis (VEE) virus infection by cell-free supernatant obtained from immune spleen cells. J. Neurol. Sci. 97:143-153.
16. Isler, P., E. Vey, J. H. Zhang, and J. M. Dayer. 1993. Cell surface glycoproteins expressed on activated human T cells induce production of interleukin-1 beta by monocytic cells: a possible role of CD69. Eur. Cytokine Netw. 4:15-23.
17. Jackson, A. C., S. K. SenGupta, and J. F. Smith. 1991. Pathogenesis of Venezuelan equine encephalitis virus infection in mice and hamsters. Vet. Pathol. 28:410-418.
18. Johnston, R. E., and C. J. Peters. 1995. Alphaviruses, p. 843-898. In B. N. Fields, D. M. Knipe, P. M. Howley, R. M. Chanock, J. L. Melnick, T. P. Monath, B. Roizman, and S. E. Strauss (ed.), Fields virology, 3rd ed. Lippincott-Raven, Philadelphia, Pa.
19. Katre, N. V., M. J. Knauf, and W. J. Laird. 1987. Chemical modification of recombinant interleukin 2 by polyethylene glycol increases its potency in the murine Meth A sarcoma model. Proc. Natl Acad. Sci. USA 84:1487-1491.
20. Komatsu, T., M. Barna, and C. S. Reiss. 1997. Interleukin-12 promotes recovery from viral encephalitis. Viral Immunol. 10:35-47.
21. LeBlanc, P. A. 1989. Macrophage activation for cytolysis of virally infected target cells. J. Leukoc. Biol. 45:345-352.
22. Lennette, E. H., and H. Koprowski. 1943. Human infection with Venezuelan equine encephalomyelitis virus. JAMA 123:1088-1095.
23. Manie, S., J. Kubar, M. Limouse, B. Ferrua, M. Ticchioni, J. P. Breittmayer, J. F. Peyron, L. Schaffar, and B. Rossi. 1993. CD3-stimulated Jurkat T cells mediate IL-I beta production in monocytic THP-1 cells: role of LFA-1 molecule and participation of CD69 T cell antigen. Eur. Cytokine Netw. 4:7-13.
24. Orange, J. S., S. F. Wolf, and C. A. Biron. 1994. Effects of IL-12 on the response and susceptibility of experimental viral infections. J. Immunol. 152:1253-1264.
25. Pan American Health Organization. 1972. Venezuelan encephalitis, p. 7-16. In Proceedings of the Workshop. Symposium on Venezuelan encephalitis virus. Pan American Health Organization, Washington, D.C.
26. Peters, C. J., and J. M. Dalrymple. 1990. Alphaviruses, p. 713-761. In B. N. Fields and D. M. Knipe (ed.), Virology. Raven Press, New York, N.Y.
27. Phillpotts, R. J., T. J. G. Brooks, and C. S. Cox. 1997. A simple device for the exposure of animals to infectious microorganisms by the airborne route. Epidemiol. Infect. 118:71-75.
28. Phillpotts, R. J., and A. J. Wright. 1999. TC-83 vaccine protects against airborne or subcutaneous challenge with heterologous mouse-virulent strains of Venezuelan equine encephalitis virus. Vaccine 17:982-988.
29. Pittman, P. R., R. S. Makuch, J. A. Mangiafico, T. L. Cannon, P. H. Gibbs, and C. J. Peters. 1996. Long-term duration of delectable neutralizing antibodies after administration of live-attenuated VEE vaccine and following booster vaccination with inactivated VEE vaccine. Vaccine 14:337-343.
30. Ramachandran, R., D. A, Katzenstein, M. A. Winters, S. K. Kundu, and T. C. Merigan. 1996. Polyethylene glycol-modified interleukin-2 and thymosin alpha 1 in human immunodeficiency virus type 1 infection. J. Infect. Dis. 173:1005-1008.
31. Roehrig, J. T., J. W. Day, and R. M. Kinney. 1982. Antigenic analysis of the surface glycoproteins of a Venezuelan equine encephalomyelitis virus (TC-83) using monoclonal antibodies. Virology 118:269-278.
32. Ryzhikov, A. B., N. V. Tkacheva, A. N. Sergeev, and E. I. Ryabchikova. 1991. Venezuelan equine encephalitis virus propagation in the olfactory tract of normal and immunized mice. Biomed. Sci. 2:607-614.
33. Samuel, C. E. 1991. Antiviral actions of interferon, interferon-regulated cellular proteins and their surprisingly selective antiviral activities. Virology 183:1-11.
34. Spotts, D. R., R. M. Reich, M. A. Kalkhan, R. M. Kinney, and J. T. Roehrig. 1998. Resistance to alpha/beta interferons correlates with the epizootic and virulence potential of Venezuelan equine encephalitis viruses and is determined by the 5′ noncoding region and glycoproteins. J Virol. 72:10286-10291.
35. Sun, S., X. Zhang, D. F. Tough, and J. Sprent. 1998. Type 1 interferon-mediated stimulation of T cells by CpG DNA. J. Exp. Med. 188:2335-2342.
36. Teppler, H., G. Kaplan, K. A. Smith, A. L. Montana, P. Meyn, and Z. A. Cohn. 1993. Prolonged immunostimulatory effect of low-dose polyethylene glycol interleukin 2 in patients with human immunodeficiency virus type 1 infection. J. Exp. Med. 177:483-492.
37. Testi, R., J. H. Phillips, and L. L. Lanier. 1989. T cell activation via Leu-23 (CD69). J. Immunol. 143:1123-1128.
38. Tsutsumi, Y., T. Kihira, S. Tsunoda, H. Kamada, S. Nakagawa, Y. Kaneda, T. Kanamori, and T. Mayumi. 1996. Molecular design of hybrid tumour necrosis factor-alpha III: polyethylene glycol-modified tumour necrosis factor-alpha has markedly enhanced antitumour potency due to longer plasma half-life and higher tumour accumulation. J. Pharmacol. Exp. Ther. 278: 1006-1011.
39. Vilanova, M., D. Tavares, P. Ferreira, L. Oliveira, A. Nobrega, R. Appelberg, and M. Arala-Chaves. 1996. Role of monocytes in the up-regulation of the early activation marker CD69 on B and T murine lymphocytes induced by microbial mitogens. Scand. J. Immunol. 43:155-163.
40. Vogel, P., D. Abplanalp, W. Kell, M. S. Ibrahim, M. B. Downs, W. D. Pratt, and K. J. Davis. 1996. Venezuelan equine encephalitis in BALB/c mice: kinetic analysis of central nervous system infection following aerosol or subcutaneous inoculation. Arch. Pathol. Lab. Med. 120:164-172.
41. Wright, A. W., and R. J. Phillpotts. 1998. Humane endpoints are an objective measure of morbidity in Venezuelan encephalomyelitis virus infection in mice. Arch. Virol. 141:71-75.
42. Zajac, A. J., J. N. Blattman, K. Murali-Krishna, D. J. D. Sourdive, M. Suresh, J. D. Altman, and R. Ahmed. 1998. Viral immune evasion due to persistence of activated T cells without effector function. J. Exp. Med. 188: 2205-2213.